# A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct06938321/  
OnCo record `nct06938321` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AK112 in biliary tract cancer, run by Akeso, now recruiting.

## Summary

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT06938321 by Akeso, with 135 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-05. Interventions recorded: AK112 and AK130.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06938321
- Phase: 1/2
- Setting: An Open Label, Multicenter, Phase Ib/II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
- Sponsor: Akeso
- Enrolled: 135

## Sources

- ClinicalTrials.gov NCT06938321: https://clinicaltrials.gov/study/NCT06938321

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06938321.json